vs
ANI PHARMACEUTICALS INC（ANIP）とMARCUS CORP（MCS）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $193.5M、MARCUS CORPの約1.3倍）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 2.8%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $26.4M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 18.2%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
マーカス社はアメリカの企業で、アメリカとカナダを事業エリアとして、商業用不動産分野における不動産仲介、住宅ローン仲介、調査、コンサルティングサービスを提供しています。1社の仲介業者による独占的な物件公開の慣行を普及させ、現在は両国に80以上の拠点を置き、1800人を超える従業員を擁しています。
ANIP vs MCS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $193.5M |
| 純利益 | $27.5M | — |
| 粗利率 | — | — |
| 営業利益率 | 14.1% | 0.9% |
| 純利益率 | 11.1% | — |
| 売上前年比 | 29.6% | 2.8% |
| 純利益前年比 | 367.5% | — |
| EPS（希薄化後） | $1.14 | — |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $193.5M | ||
| Q3 25 | $227.8M | $210.2M | ||
| Q2 25 | $211.4M | $206.0M | ||
| Q1 25 | $197.1M | $148.8M | ||
| Q4 24 | $190.6M | $188.3M | ||
| Q3 24 | $148.3M | $232.7M | ||
| Q2 24 | $138.0M | $176.0M | ||
| Q1 24 | $137.4M | $138.5M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $16.2M | ||
| Q2 25 | $8.5M | $7.3M | ||
| Q1 25 | $15.7M | $-16.8M | ||
| Q4 24 | $-10.3M | $986.0K | ||
| Q3 24 | $-24.2M | $23.3M | ||
| Q2 24 | $-2.3M | $-20.2M | ||
| Q1 24 | $18.2M | $-11.9M |
| Q4 25 | 14.1% | 0.9% | ||
| Q3 25 | 15.9% | 10.8% | ||
| Q2 25 | 6.6% | 6.3% | ||
| Q1 25 | 13.3% | -13.7% | ||
| Q4 24 | -2.3% | -1.2% | ||
| Q3 24 | -13.8% | 14.1% | ||
| Q2 24 | 3.7% | 1.3% | ||
| Q1 24 | 14.8% | -12.0% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | 7.7% | ||
| Q2 25 | 4.0% | 3.6% | ||
| Q1 25 | 8.0% | -11.3% | ||
| Q4 24 | -5.4% | 0.5% | ||
| Q3 24 | -16.3% | 10.0% | ||
| Q2 24 | -1.7% | -11.5% | ||
| Q1 24 | 13.2% | -8.6% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $0.82 | — |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $23.4M |
| 総負債低いほど良い | — | $159.0M |
| 株主資本純資産 | $540.7M | $457.4M |
| 総資産 | $1.4B | $1.0B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.35× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $23.4M | ||
| Q3 25 | $262.6M | $7.4M | ||
| Q2 25 | $217.8M | $14.9M | ||
| Q1 25 | $149.8M | $11.9M | ||
| Q4 24 | $144.9M | $40.8M | ||
| Q3 24 | $145.0M | $28.4M | ||
| Q2 24 | $240.1M | $32.8M | ||
| Q1 24 | $228.6M | $17.3M |
| Q4 25 | — | $159.0M | ||
| Q3 25 | — | $162.0M | ||
| Q2 25 | — | $179.9M | ||
| Q1 25 | — | $198.9M | ||
| Q4 24 | — | $159.1M | ||
| Q3 24 | — | $173.1M | ||
| Q2 24 | — | $175.7M | ||
| Q1 24 | — | $169.8M |
| Q4 25 | $540.7M | $457.4M | ||
| Q3 25 | $505.8M | $454.3M | ||
| Q2 25 | $436.8M | $448.4M | ||
| Q1 25 | $418.6M | $441.8M | ||
| Q4 24 | $403.7M | $464.9M | ||
| Q3 24 | $405.9M | $462.3M | ||
| Q2 24 | $455.8M | $449.4M | ||
| Q1 24 | $452.0M | $459.3M |
| Q4 25 | $1.4B | $1.0B | ||
| Q3 25 | $1.4B | $1.0B | ||
| Q2 25 | $1.3B | $1.0B | ||
| Q1 25 | $1.3B | $1.0B | ||
| Q4 24 | $1.3B | $1.0B | ||
| Q3 24 | $1.3B | $1.0B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.0B |
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.39× | ||
| Q1 24 | — | 0.37× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $48.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $26.4M |
| FCFマージンFCF / 売上 | 11.8% | 13.6% |
| 設備投資強度設備投資 / 売上 | 0.5% | 11.6% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | — |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $989.0K |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $48.8M | ||
| Q3 25 | $44.1M | $39.1M | ||
| Q2 25 | $75.8M | $31.6M | ||
| Q1 25 | $35.0M | $-35.3M | ||
| Q4 24 | $15.9M | $52.6M | ||
| Q3 24 | $12.5M | $30.5M | ||
| Q2 24 | $17.4M | $36.0M | ||
| Q1 24 | $18.3M | $-15.1M |
| Q4 25 | $29.1M | $26.4M | ||
| Q3 25 | $38.0M | $18.2M | ||
| Q2 25 | $71.8M | $14.7M | ||
| Q1 25 | $32.5M | $-58.3M | ||
| Q4 24 | $13.5M | $27.1M | ||
| Q3 24 | $7.7M | $12.0M | ||
| Q2 24 | $13.0M | $16.1M | ||
| Q1 24 | $13.7M | $-30.5M |
| Q4 25 | 11.8% | 13.6% | ||
| Q3 25 | 16.7% | 8.7% | ||
| Q2 25 | 34.0% | 7.1% | ||
| Q1 25 | 16.5% | -39.2% | ||
| Q4 24 | 7.1% | 14.4% | ||
| Q3 24 | 5.2% | 5.2% | ||
| Q2 24 | 9.4% | 9.2% | ||
| Q1 24 | 10.0% | -22.0% |
| Q4 25 | 0.5% | 11.6% | ||
| Q3 25 | 2.7% | 9.9% | ||
| Q2 25 | 1.9% | 8.2% | ||
| Q1 25 | 1.3% | 15.5% | ||
| Q4 24 | 1.3% | 13.5% | ||
| Q3 24 | 3.2% | 7.9% | ||
| Q2 24 | 3.2% | 11.3% | ||
| Q1 24 | 3.3% | 11.1% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 2.41× | ||
| Q2 25 | 8.87× | 4.32× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 53.31× | ||
| Q3 24 | — | 1.31× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
